Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice

MLA

Álamo MC, et al. Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice. Jan. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..aae155617fda2fe6c71f44df79e8c836&authtype=sso&custid=ns315887.

APA

Álamo MC, Ochenduszko S, Crespo G, Corral M, Oramas J, Sancho P, Medina J, Garicano F, López P, Campos Balea B, Rodríguez Garzotto A, & Muñoz-Couselo E. (2021). Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice.

Chicago

Álamo MC, Ochenduszko S, Crespo G, Corral M, Oramas J, Sancho P, Medina J, et al. 2021. “Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..aae155617fda2fe6c71f44df79e8c836&authtype=sso&custid=ns315887.